How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,431 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02862028 Recruitment Status : Unknown Verified August 2016

2016 Clinical Trials

82. PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02873390 Recruitment Status : Unknown Verified August 2016 by Ningbo Cancer Hospital. Recruitment status was: Recruiting First Posted

2016 Clinical Trials

83. Views of Medical Doctors Regarding the 2013 WHO Adult HIV Treatment Guidelines Indicate Variable Applicability for Routine Patient Monitoring, for Their Family Members and for Themselves, in South-Africa Full Text available with Trip Pro

Views of Medical Doctors Regarding the 2013 WHO Adult HIV Treatment Guidelines Indicate Variable Applicability for Routine Patient Monitoring, for Their Family Members and for Themselves, in South-Africa South African doctors (n = 211) experienced in antiretroviral therapy use were asked via an online questionnaire about the WHO 2013 adult antiretroviral integrated guidelines, as well as clinical and personal issues, in three hypothetical scenarios: directing the Minister of Health, advising (...) a family member requiring therapy amidst unstable antiretroviral supplies, and where doctors themselves were HIV-positive. Doctors (54%) favoured the 500 cells/μl WHO initiation threshold if advising the Minister; a third recommended retaining the 350 cells/μl threshold used at the time of the survey. However, they favoured a higher initiation threshold for their family member. Doctors were 4.9 fold more likely to initiate modern treatment, irrespective of their CD4 cell count, for themselves than

2016 PloS one

84. Guiding and supporting adolescents living with HIV in sub-Saharan Africa: The development of a curriculum for family and community members Full Text available with Trip Pro

(FMP) is an evidence-based intervention for parents and caregivers of 9-12 year-olds that promotes positive parenting practices and effective parent-child communication about sexuality and sexual risk reduction. It is delivered to groups of participants at the community level through a series of six weekly three-hour sessions. Recognizing family and community members' need for guidance on issues specific to ALHIV, we developed a seventh FMP session to address their needs. Key themes treated (...) Guiding and supporting adolescents living with HIV in sub-Saharan Africa: The development of a curriculum for family and community members Although HIV-related deaths declined globally by 30% between 2005 and 2012, those among adolescents living with HIV (ALHIV) rose by 50%. This discrepancy is primarily due to failure to address the specific needs of ALHIV and resulting poor clinical outcomes related to late diagnosis and poor adherence to antiretroviral therapy. The Families Matter! Program

2016 Children and youth services review

85. Delayed Adrenarche may be an Additional Feature of Immunoglobulin Super Family Member 1 Deficiency Syndrome Full Text available with Trip Pro

Delayed Adrenarche may be an Additional Feature of Immunoglobulin Super Family Member 1 Deficiency Syndrome Immunoglobulin super family member 1 (IGSF1) deficiency syndrome is characterized by central hypothyroidism, delayed surge in testosterone during puberty, macro-orchidism, and in some cases, hypoprolactinemia and/or transient growth hormone (GH) deficiency. Our patient was a 19-year-old male adolescent who had been treated since the age of 9 years with GH and thyroxine for an idiopathic

2016 Journal of clinical research in pediatric endocrinology

86. Lymphoid tissue-resident commensal bacteria promote members of the IL-10 cytokine family to establish mutualism Full Text available with Trip Pro

. In germ-free and antibiotic-treated mice, LRCs colonized intestinal lymphoid tissues and induced multiple members of the IL-10 cytokine family, including dendritic-cell-derived IL-10 and group 3 innate lymphoid cell (ILC3)-derived IL-22. Notably, IL-10 limited the development of pro-inflammatory Th17 cell responses, and IL-22 production enhanced LRC colonization in the steady state. Furthermore, LRC colonization protected mice from lethal intestinal damage in an IL-10-IL-10R-dependent manner (...) Lymphoid tissue-resident commensal bacteria promote members of the IL-10 cytokine family to establish mutualism Physical separation between the mammalian immune system and commensal bacteria is necessary to limit chronic inflammation. However, selective species of commensal bacteria can reside within intestinal lymphoid tissues of healthy mammals. Here, we demonstrate that lymphoid-tissue-resident commensal bacteria (LRC) colonized murine dendritic cells and modulated their cytokine production

2016 Immunity

87. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor Full Text available with Trip Pro

Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor Malignant peripheral nerve sheath tumors (MPNST) are rare, highly malignant, and poorly understood sarcomas. The often poor outcome of MPNST highlights the necessity of identifying prognostic predictors for this aggressive sarcoma. Here, we investigate the role of fibroblast growth factor receptor (FGFR) family members in human MPNSTs.aCGH and bioinformatics analysis identified (...) of MPNST with better OS. FGFR4 protein was expressed 82.3% of MPNST samples, and was associated with poor disease-free survival.We performed microarray-based comparative genomic hybridization (aCGH) profiling of two cohorts of primary MPNST tissue samples including 25 patients treated at The University of Texas MD Anderson Cancer Center and 26 patients from Tianjin Medical University Cancer Institute and Hospital. Fluorescence in situ hybridization (FISH) was used to validate the gene amplification

2016 Oncotarget

88. MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway Full Text available with Trip Pro

MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway MicroRNA-126 (miR-126) suppresses the migration, proliferation and invasion of colon cancer cells. However, the underlying mechanisms of miR-126 in colon cancer have not been fully elucidated. In this study, in vivo experiments revealed that miR-126 inhibits colon cancer growth and metastasis. Furthermore, miR-126 (...) was down-regulated in human colon cancer tissue, and its expression was inversely correlated with TNM stage and metastasis of patients. Low level of miR-126 identified patients with poor prognosis. And we found that miR-126 expression was negatively correlated with the expression levels of chemokine (C-X-C motif) receptor 4 (CXCR4) and components of signaling pathway of Ras homolog gene family, member A (RhoA) in vitro and in vivo. Moreover, we verified that miR-126 negatively regulated CXCR4 and RhoA

2016 Oncotarget

89. Mineralocorticoid Receptor (MR) trans-Activation of Inflammatory AP-1 Signaling: DEPENDENCE ON DNA SEQUENCE, MR CONFORMATION, AND AP-1 FAMILY MEMBER EXPRESSION Full Text available with Trip Pro

Mineralocorticoid Receptor (MR) trans-Activation of Inflammatory AP-1 Signaling: DEPENDENCE ON DNA SEQUENCE, MR CONFORMATION, AND AP-1 FAMILY MEMBER EXPRESSION Glucocorticoids are commonly used to treat inflammatory disorders. The glucocorticoid receptor (GR) can tether to inflammatory transcription factor complexes, such as NFκB and AP-1, and trans-repress the transcription of cytokines, chemokines, and adhesion molecules. In contrast, aldosterone and the mineralocorticoid receptor (MR (...) ) primarily promote cardiovascular inflammation by incompletely understood mechanisms. Although MR has been shown to weakly repress NFκB, its role in modulating AP-1 has not been established. Here, the effects of GR and MR on NFκB and AP-1 signaling were directly compared using a variety of ligands, two different AP-1 consensus sequences, GR and MR DNA-binding domain mutants, and siRNA knockdown or overexpression of core AP-1 family members. Both GR and MR repressed an NFκB reporter without influencing

2016 The Journal of biological chemistry

90. Impact of medical assistance in dying on family and friends

clear procedures to follow, and shared responsibilities between patients, family members, and healthcare providers (1). In several studies, the family and friends of patients who requested medical assistance in dying had less traumatic grief symptoms compared to family and friends of patients who died of natural causes (2-4). However, other studies have shown a higher prevalence of post-traumatic stress disorder (PTSD) and depression among family members or friends witnessing medical assistance (...) in dying (5). Some studies found that the opportunity to discuss death freely and extensively in an open atmosphere with a loved one may make it easier to come to terms with an impending death (4, 6-8). Acknowledgement of the experiences of family members should be an essential component of all research investigating medical assistance in dying (1). Note: Studies included in this review use the terms “medical assistance in dying”, “euthanasia”, “assisted suicide”, “physician-assisted suicide

2017 Ontario HIV Treatment Network

91. Engaging High Risk Families in Home Visiting Programs: A Rapid Review

should treat parents in a non- stigmatizing and supportive way. (8) Uptake of home visiting programs is influenced by parents’ perceived needs, confidence levels and desire for practical support. (6) Participation is also influenced by families’ culture and language. (6) Parental perception of the quality of the intervention can be affected when parents worry about staff prying into their personal lives. (6) If a program targets ‘disadvantaged’ families, this label may accentuate the sense of failure (...) the length or frequency of visits, and providing flexible hours, including evenings and weekends, allows working parents, partners, and other family members to participate. (6-8) When a client is disengaged and may consider dropping out, staff should change the content being delivered and/or offer a break from the program. (6) During breaks from the program, the nurse should maintain regular communication with parents. (6) It is key that staff are flexible to the needs of the client by ensuring services

2018 Peel Health Library

92. Marriage and Family Building Equality for Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual, and Gender Nonconforming Individuals

resources. Obstetrician–gynecologists should do the following: Work to understand, recognize, and address the challenges the LGBTQIA and gender nonconforming communities experience in accessing reproductive health care, including family building. Work to eliminate overt and covert discriminatory procedures and practices in their clinical spaces through creation of affirming and welcoming environments. Understand that members of the LGBTQIA and gender nonconforming communities may desire family building (...) in accessing the resources available to support the health and growth of their families. Research has consistently demonstrated that members of these communities can provide loving, safe, and healthy homes for children ( ). Family building for these communities includes multiple modalities, but some may require assisted reproductive technologies or adoption ( , ). Persistent stigmatization of the LGBTQIA and gender nonconforming communities may result in difficulty finding physicians to assist

2018 American College of Obstetricians and Gynecologists

93. Treating Opioid Use Disorder During Pregnancy: Guideline Supplement

. The application of the recommendations in this guideline does not override the responsibility of health care professionals to make decisions appropriate to the circumstances of an individual patient, in consultation with that patient and their guardian(s) or family members, and, when appropriate, external experts (e.g., specialty consultation). Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. Legal Disclaimer While the individuals (...) Treating Opioid Use Disorder During Pregnancy: Guideline Supplement 1 Guideline Supplement Treatment of Opioid Use Disorder During2 THIS IS A BLANK PAGE3 A Guideline for the Clinical Management of Opioid Use Disorder—Pregnancy Supplement The BC Centre on Substance Use (BCCSU) is a provincially networked platform mandated to develop, imple- ment, and evaluate evidence-based approaches to substance use and addiction. The BCCSU’s focus is on three strategic areas including research and evaluation

2018 British Columbia Perinatal Health Program

94. Eliglustat for treating type 1 Gaucher disease

project team 43 Evaluation committee members 43 NICE project team 43 Eliglustat for treating type 1 Gaucher disease (HST5) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 441 1 Recommendations Recommendations 1.1 Eliglustat is recommended within its marketing authorisation for treating type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive (...) Eliglustat for treating type 1 Gaucher disease Eliglustat for treating type 1 Gaucher Eliglustat for treating type 1 Gaucher disease disease Highly specialised technologies guidance Published: 28 June 2017 nice.org.uk/guidance/hst5 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

95. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia

committee members 21 NICE project team 21 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute (...) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Blinatumomab for pre Blinatumomab for previously treated viously treated Philadelphia-chromosome-negativ Philadelphia-chromosome-negative e acute lymphoblastic leukaemia acute lymphoblastic leukaemia T echnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta450 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

96. Obeticholic acid for treating primary biliary cholangitis

discussion 7 Clinical management of primary biliary cholangitis 7 Clinical effectiveness of obeticholic acid 9 Adverse events 10 Cost effectiveness 10 Innovation 15 Other considerations 15 Pharmaceutical Price Regulation Scheme (PPRS) 2014 16 Summary of appraisal committee's key conclusions 16 5 Implementation 22 6 Appraisal committee members and NICE project team 23 Appraisal committee members 23 NICE project team 23 Obeticholic acid for treating primary biliary cholangitis (TA443) © NICE 2018. All (...) of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to Ruth Nasr on 020 3805 7531 or email ruth.nasr@interceptpharma.com. Obeticholic acid for treating primary biliary cholangitis (TA443) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 22 of 246 6 Appr Appraisal committee me aisal committee members and NICE project team mbers and NICE

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

97. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

of appraisal committee's key conclusions 22 5 Implementation 30 6 Appraisal committee members, guideline representatives and NICE project team 31 Appraisal committee members 31 NICE project team 31 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 321 1 Recommendations (...) Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation Ibrutinib for pre Ibrutinib for previously treated chronic viously treated chronic lymphocytic leukaemia and untreated lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p chronic lymphocytic leukaemia with 17p deletion or TP53 mutation deletion or TP53 mutation T echnology appraisal guidance Published: 25 January 2017 nice.org.uk

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

98. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens

members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 25This guidance replaces TA250. This guidance should be read in conjunction with TA515. 1 1 Recommendations Recommendations 1.1 Eribulin is recommended as an option (...) with locally advanced or metastatic breast cancer, whose disease has progressed after at least 2 chemotherapy regimens. The committee concluded that eribulin is particularly valuable, and has been more widely used, for HER2-negative disease because this has fewer treatment options. It also recognised that the availability of additional treatment options for advanced disease would be valued by patients and their families. 4.1 to 4.3 The technology The technology Eribulin for treating locally advanced

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

99. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

guidance 241) 19 Cancer Drugs Fund partial reconsideration of NICE technology appraisal guidance 241 19 Summary of appraisal committee's key conclusions 21 5 Implementation 31 6 Appraisal committee members and NICE project team 32 Appraisal committee members 32 NICE project team 32 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia Dasatinib, nilotinib and high-dose Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or imatinib for treating imatinib-resistant or intoler intolerant chronic m ant chronic my yeloid leukaemia eloid leukaemia T echnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425 © NICE 2018. All rights reserved. Subject to Notice of rights

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

100. Venetoclax for treating chronic lymphocytic leukaemia

Symptoms and management of CLL 7 Clinical effectiveness 9 Indirect comparison with best supportive care 12 Cost effectiveness 13 Cancer Drugs Fund considerations 20 Summary of appraisal committee's key conclusions 22 5 Implementation 30 6 Recommendations for data collection 31 7 Appraisal committee members and NICE project team 32 Appraisal committee members 32 NICE project team 32 Venetoclax for treating chronic lymphocytic leukaemia (TA487) © NICE 2018. All rights reserved. Subject to Notice (...) Venetoclax for treating chronic lymphocytic leukaemia V Venetoclax for treating chronic enetoclax for treating chronic lymphocytic leukaemia lymphocytic leukaemia T echnology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>